Category: PSYCH STOCK NEWS

Silo Pharma (SILO) Attends Dawson James Conference.

We watched an excellent presentation from management at the Dawson conference and starting our due diligence now. Primary item of our interest is a joint...

PharmaTher (PHRM, PHRRF) $0.10 Gets $3.80 Price Target From H.C. Wainwright – 37 Times (3,700%) Higher.

Thus, to us, the key potential positive events that could lead to a rerating in PHRM.CN shares include publication of the Phase 2 trial data evaluating ketamine in LID-PD in...

Ehave, Inc. Announces its KetaDASH Mobile Unit Delivered to Miami Beach.

MIAMI, June 03, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its KetaDASH subsidiary will accept delivery of...

Australian Icannex (IHL:ASX) Headed to NASDAQ?

Incannex completes Phase 2 trial for its cannabinoid drug for sleep apnea, flags Nasdaq listing in 2022 With Phase 2 dosing complete,...

Mycotopia Therapies (TPIA) $1.65, Issues CEO Letter to Stockholders, Reports on Significant Progress and Outlook for 2021

Mycotopia Therapies looking to unlock the full potential of psychedelic-derived medicines; Create Active Pharmaceutical Ingredient (API) for magic mushroom MIAMI, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mycotopia...

Small Pharma (DMT, DMTTF) $0.46 a Small and Extremely Interesting Psychedelic Company.

Conference Call Today at 12:00 EST. As the TSX chart above show, investors appear to be warming up the the idea. Not many investors...

Mindcure (MCURF) and Awakn Life Sciences (AWKNF) Seek to Distribute Ketamine Protocol for Alcohol Use Disorder.

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE's Digital Therapeutics Platform

Psychedelic Drugs ‘Far Exceed’ Cannabis Investment Potential (CNBC)

Shark Tank’s Kevin O’Leary, Wesana (WSNAF) CEO Daniel Carcillo and director at Mass General Hospital’s Center for the Neuroscience of Psychedelics Dr. Sharmin Ghaznavi. Recent Wall Street...
Most Popular

Awakn Life Sciences (AWKNF) $0.30 Announces Signing of Lease for Second Clinic in Norway.

Trondheim in central Norway will be the location of Awakn's 4th clinic LIVE QUOTE

Silo Pharma (SILO) Issues Letter to Shareholders

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine LIVE QUOTE

Silo Pharma (SILO) $3.36 Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

View Post ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage...